Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore recently spoke with experienced business writer, Tim Boreham, for his Dr Boreham's Crucible column which was published in Biotech Daily on Friday night and then reproduced in Stockhead across the weekend.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
The 2018-2019 year has been a year of transition for Anatara Lifesciences (ASX:ANR), having commenced the year with a clear focus on successfully evolving into a human health company, through the pursuit of the burgeoning gastrointestinal health market.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30th June 2019.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the Monsoon Communications Twilight Investor Briefing, yesterday evening, in Melbourne.
Anatara Lifesciences Ltd's (ASX:ANR) CEO, Steve Lydeamore will be presenting to investors at a Monsoon Communications Twilight Investor Briefing event in Melbourne next week. Investors interested in attending this presentation are invited to reach out.
Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets (known as scour), with potential application in other livestock animals, aquaculture and companion animals.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the 15th Bioshares Biotech Summit, held in Queenstown, New Zealand, 26th to 27th July 2019.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th June 2019. The Company's cash plus term deposits at the end of the quarter stood at $5.4m. On 30th June 2019, the Company had cash at bank of $1,360,086 and $4,050,000 in term deposits. Expenditure during the quarter was in line with forecast.
Anatara's CEO, Steve Lydeamore will be presenting to investors during the Bioshares Biotech Summit this Friday, and at a Monsoon Communications Twilight Investor Briefing event in Melbourne during August.
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a SPEC BUY rating and a 12-month price target of $0.90 per share.